-
Mashup Score: 9STAT Expert Advantage - 4 year(s) ago
How will companies, patients, and the FDA navigate the impact of COVID-19 on Clinical Trials? A conversation with the former Director of the FDA Orphan Drug Division.
Source: Slingshot InsightsCategories: General Medicine NewsTweet
-
Mashup Score: 2STAT Expert Advantage - 4 year(s) ago
How will companies, patients, and the FDA navigate the impact of COVID-19 on Clinical Trials? A conversation with the former Director of the FDA Orphan Drug Division.
Source: Slingshot InsightsCategories: General Medicine NewsTweet-
How will the coronavirus pandemic impact the development and @US_FDA review of drugs for rare diseases? Join this month’s STAT Expert Advantage call to listen in as @adamfeuerstein and Dr. Marlene Haffner discuss. Save your spot here: https://t.co/MLhV5JWjeB #STATExpertAdvantage https://t.co/Ty7dccWY3D
-
-
Mashup Score: 4STAT Expert Advantage - 4 year(s) ago
How will companies, patients, and the FDA navigate the impact of COVID-19 on Clinical Trials? A conversation with the former Director of the FDA Orphan Drug Division.
Source: Slingshot InsightsCategories: General Medicine NewsTweet-
How will the coronavirus pandemic impact the development and @US_FDA review of drugs for rare diseases? Join this month’s STAT Expert Advantage call to listen in as @adamfeuerstein and Dr. Marlene Haffner discuss. https://t.co/C8m3ce8Fnl #STATExpertAdvantage
-
-
Mashup Score: 0STAT Expert Advantage - 4 year(s) ago
After a positive FDA panel for Aimmune’s and FDA decision looming, we will discuss the commercial potential of Palforzia. NOTE: Call will have a proprietary survey, run by SI, of high volume pediatric allergists/immunologists available.
Source: Slingshot InsightsCategories: General Medicine NewsTweet-
STAT’s @adamfeuerstein will host our January conference call, “The commercial potential of Palforzi.” Join STAT Expert Advantage to tune in: https://t.co/Yec3Q3fPIC #STATExpertAdvantage https://t.co/bnkX8ss7cW
-
#COVID19 has forced the FDA to make changes to clinical trial reviews. Join our next STAT Expert Advantage call to hear @adamfeuerstein and Dr. Marlene Haffner discuss the impact this could have on clinical trials for orphan drugs: https://t.co/yt1nVMaUcu #STATExpertAdvantage https://t.co/ALca5bXOyh